The phase 3b study shows Ebglyss reduced eczema severity and itch in challenging areas, with 60% of prior dupilumab patients meeting key improvement by week 24.
News
All News
Joel Gelfand, MD, discusses insights on complex psoriasis cases, comorbidity management, and the evolving role of phototherapy at Fall Clinical 2024.
Adbry achieved EASI-75 in 92.9% and IGA 0/1 in 66.7% of AD patients, with a strong safety profile.
Sun Pharma presented long-term data on Leqselvi 8 mg tablets, showing significant scalp hair regrowth in severe alopecia areata patients.
Catch up on coverage from the second day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.
Shawn Kwatra, MD, reviews key highlights of his sessions at Fall Clinical 2024 on the latest updates in itch conditions.
Shahriari highlighted advanced dermatology treatments, clinical trial inclusivity, and key care strategies for complex skin conditions at Fall Clinical 2024.
Del Rosso reviews available and upcoming monoclonal antibodies, including nemolizumab, lebrikizumab, bimekizumab, and more.
Phase 3b study showed promise in clearing moderate PsO in sensitive areas for patients unresponsive to topical treatments.
Christopher Bunick, MD, PhD, presented the latest period 2 data at Fall Clinical 2024.
This review of the latest dermatologic studies includes discussions on the development of the Hand Eczema Impact Scale, the role of tofacitinib on Th1 and Th2 cytokines, and more.
Catch up on coverage from the first day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.
Clinicians presented a panel-style session at Fall Clinical, touching on the drawbacks of topical steroid use and alternatives in AD patients.
Del Rosso reviews numerous new and upcoming topical therapeutics and indications including ruxolitinib, tapinarof, and more.
Among the many sessions to be held at the Fall Clinical Dermatology Conference in Las Vegas, Nevada, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.
The conference will feature presentations on a number of disease states, therapeutic options, and new clinical data.
Share with us the topics you want to learn more about at Fall Clinical.
The late-breaking data will be presented at ACAAI’s annual Scientific Meeting.
Findings from 2 phase 3 trials indicate that ZORYVE cream significantly improves both clinical outcomes and quality of life in patients with mild to moderate atopic dermatitis.
The conference aimed at providing dermatology clinicians with the latest in the specialty begins today in Las Vegas, Nevada.
Survey results presented at ACAAI’s annual Scientific Meeting demonstrate the limited influence of elimination diets for reducing symptoms of AD.
The application of a clinically validated moisturizer before mask-wearing was shown to significantly improve skin barrier function and reduce irritation.
We want to know: Will you be attending the conference in Las Vegas later this week?
In a Dermatology Times Case-Based Roundtable event, Ted Lain, MD, MBA, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib.
Christopher Bunick, MD, PhD, addresses common barriers in recognizing and treating chronic hand eczema and its significant impact on quality of life.
Understanding the varying tax aspects of S corporations and C corporations is an important first step in determining which structure will work best for your practice.
In a recent Dermatology Times DermView video series, “Advancing Care in Pediatric Plaque Psoriasis: Emerging Treatments and Management Strategies," Karan Lal, DO, and Helen Shin, MD, discuss pediatric psoriasis and its prevalence.
Researchers behind a recent study found that patients with liver disease had a significantly higher prevalence of chronic pruritus.
In a Dermatology Times Case-Based Roundtable event, Heather Woolery-Lloyd, MD, shared pearls for challenging acne cases.
